We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+9.49%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$142M
AUM Growth
-$445K
Cap. Flow
-$1.24M
Cap. Flow %
-0.88%
Top 10 Hldgs %
76.61%
Holding
63
New
3
Increased
5
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
BDSX icon
Biodesix
BDSX
+$3.63M
2
ATEC icon
Alphatec Holdings
ATEC
+$806K
3
ELUT icon
Elutia
ELUT
+$608K
4
HALO icon
Halozyme
HALO
+$512K
5
PRTA icon
Prothena Corp
PRTA
+$483K

Top Sells

Rank Stock Value
1
CLR
CONTINENTAL RESOURCES INC.
CLR
+$2.58M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$1.12M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$1.03M
4
NARI
Inari Medical, Inc. Common Stock
NARI
+$726K
5
VTYX
Ventyx Biosciences
VTYX
+$681K

Sector Composition

Rank Sector Weight
1 Healthcare 95.64%
2 Energy 4.26%
3 Consumer Staples 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
1
Bristol-Myers Squibb
BMY
$124B
$52.4M 36.99%
727,785
– –
BDSX icon
2
Biodesix
BDSX
$209M
$11.6M 8.19%
251,982
+133,478
+113% +$3.63M
NBIX icon
3
Neurocrine Biosciences
NBIX
$17.2B
$10.1M 7.11%
84,240
-1,000
-1% -$117K
PRTA icon
4
Prothena Corp
PRTA
$453M
$7.66M 5.41%
127,195
+8,250
+7% +$483K
ELUT icon
5
Elutia
ELUT
$42M
$6.44M 4.55%
1,515,184
+97,061
+7% +$608K
QDEL icon
6
QuidelOrtho
QDEL
$1.19B
$5.25M 3.71%
61,306
– –
OVV icon
7
Ovintiv
OVV
$16.2B
$4.27M 3.02%
84,200
– –
UTHR icon
8
United Therapeutics
UTHR
$22.7B
$4.17M 2.95%
15,000
– –
ACAD icon
9
Acadia Pharmaceuticals
ACAD
$4.38B
$3.97M 2.8%
249,400
– –
PHR icon
10
Phreesia
PHR
$662M
$2.68M 1.89%
82,700
– –
HROW icon
11
Harrow
HROW
$1.74B
$2.66M 1.88%
180,000
– –
ALBO
12
DELISTED
Albireo Pharma Inc
ALBO
$2.53M 1.79%
117,000
– –
MASI
13
DELISTED
Masimo
MASI
$2.26M 1.6%
15,280
– –
INBX
14
DELISTED
Inhibrx, Inc. Common Stock
INBX
$1.74M 1.23%
70,448
– –
FHTX icon
15
Foghorn Therapeutics
FHTX
$305M
$1.69M 1.19%
264,843
– –
AXDX
16
DELISTED
Accelerate Diagnostics
AXDX
$1.59M 1.12%
225,239
– –
AVEO
17
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$1.5M 1.06%
100,000
-40,000
-29% -$554K
ALKS icon
18
Alkermes
ALKS
$8.79B
$1.31M 0.92%
50,000
– –
CYTK icon
19
Cytokinetics
CYTK
$10.9B
$1.15M 0.81%
25,000
– –
ATEC icon
20
Alphatec Holdings
ATEC
$1.31B
$1.11M 0.79%
90,000
+80,000
+800% +$806K
CORT icon
21
Corcept Therapeutics
CORT
$9.72B
$1.02M 0.72%
50,000
– –
KPTI icon
22
Karyopharm Therapeutics
KPTI
$216M
$991K 0.7%
19,422
+1,467
+8% +$102K
ETRN
23
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
$891K 0.63%
133,050
– –
PXD
24
DELISTED
Pioneer Natural Resource Co.
PXD
$868K 0.61%
3,800
– –
DCGO icon
25
DocGo
DCGO
$64.3M
$778K 0.55%
110,000
– –
1
2 3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q4 2022 Portfolio in Review

As of Q4 2022, Birchview Capital held 63 positions worth $142M, down 0.31% from $142M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Birchview Capital's Q4 2022 filing shows 3 new, 5 increased, 7 reduced and 6 closed positions. Its largest new stake was Halozyme: 10,000 shares worth $569K. The largest sale was CONTINENTAL RESOURCES INC., an estimated $2.58M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 93% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q4 2022 buy was Halozyme: 10,000 shares worth $569K.
  • Birchview Capital added most to Biodesix in Q4 2022, an estimated $3.63M increase.
  • Birchview Capital's biggest Q4 2022 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $1.12M.
  • Birchview Capital fully exited CONTINENTAL RESOURCES INC. in Q4 2022, selling an estimated $2.58M.
  • Birchview Capital's ten largest holdings make up 77% of its $142M portfolio in Q4 2022.
  • Birchview Capital opened 3 new positions and closed 6 in Q4 2022.
  • Birchview Capital's portfolio value fell 0.31% quarter-over-quarter to $142M.

Based on Birchview Capital's 13F filing for Q4 2022, filed 3 Feb 2023.